CavtheRx is an inception stage biotechnology company focused on the development of a novel class of modulators of caveolin function with applicability to multiple sclerosis, uveitis, inflammatory bowel disease and traumatic brain injury. The core technology was developed in the laboratory of William Sessa (Yale University) and enables the modulation of signal transduction in vascular endothelial cells by a wide variety of cytokines.